Phase I Study Combining Parp-Inhibition With Immune Checkpoint Blockade In Women With Brca-Deficient Recurrent Ovarian Cancer

Objective: Preclinical data demonstrate a synergistic therapeutic benefit in BRCA1 ovarian cancer when poly adenosine diphosphate-ribose polymerase (PARP) inhibition is combined with immune checkpoint blockade. Based on this, a phase I study was conducted to assess the tolerability of this regimen in women with BRCA mutation-associated recurrent ovarian cancer.